Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

The Journal of infectious diseases - 1 Jun 2009

Saag Michael, Goodrich James, Fätkenheuer Gerd, Clotet Bonaventura, Clumeck Nathan, Sullivan John, Westby Mike, van der Ryst Elna, Mayer Howard

Abstract excerpt

BACKGROUND: Maraviroc, a CCR5 antagonist, is active against R5 but not X4 or dual- or mixed-tropic strains of human immunodeficiency virus type 1 (HIV-1). A phase 2b study was conducted to determine the safety and efficacy of maraviroc in combination with optimized background therapy in treatment-experienced patients infected with dual- or mixed-tropic HIV-1. METHODS: Treatment-experienced patients with an HIV-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclohexanes
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Fusion Inhibitors

Share to Least-Squares Analysis

Share to Patient Selection

Share to Placebos

Share to Triazoles

Source

Identifiers

PMID: 19432546
DOI: 10.1086/598965

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.PMID 19432546Read ↗

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.Semantic proximity Read ↗

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read ↗

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.Semantic proximity Read ↗

Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySemantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Semantic proximity Read ↗

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.Semantic proximity Read ↗

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.Semantic proximity Read ↗

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.Semantic proximity Read ↗

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.Semantic proximity Read ↗

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.Semantic proximity Read ↗

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.Semantic proximity Read ↗

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.